{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:29:57Z","timestamp":1761560997369,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.hrthm.2005.05.020","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T09:03:55Z","timestamp":1127207035000},"page":"1000-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy"],"prefix":"10.1016","volume":"2","author":[{"given":"Hector F.","family":"Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Florin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gervasio A.","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2005.05.020_bib1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1378\/chest.118.4.914","article-title":"Incidence, predictive factors and prognostic significance of supraventricular arrhythmias in congestive heart failure","volume":"118","author":"Mathew","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.hrthm.2005.05.020_bib2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation (AFFIRM)","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2005.05.020_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM200003303421302","article-title":"Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators","volume":"342","author":"Roy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2005.05.020_bib4","first-page":"77","article-title":"Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardial infarction","volume":"6","author":"Tuininga","year":"2000","journal-title":"J Card Fail"},{"issue":"suppl H","key":"10.1016\/j.hrthm.2005.05.020_bib5","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/S1520-765X(03)90017-4","article-title":"Atrial fibrillation","volume":"5","author":"Botto","year":"2003","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.hrthm.2005.05.020_bib6","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/01.CIR.0000070420.51787.A8","article-title":"Left ventricular remodeling and ventricular arrhythmias after myocardial infarction","volume":"107","author":"St. John Sutton","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.CIR.101.2.200","article-title":"Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling","volume":"101","author":"Lee","year":"2000","journal-title":"Circulation"},{"issue":"Pt II","key":"10.1016\/j.hrthm.2005.05.020_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1460-9592.2003.00036.x","article-title":"Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation","volume":"26","author":"Gensini","year":"2003","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib9","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000124487.36586.26","article-title":"Renin-angiotensin system gene polymorphisms and atrial fibrillation","volume":"109","author":"Tsai","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s100380200021","article-title":"Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy","volume":"47","author":"Ogimoto","year":"2002","journal-title":"J Hum Genet"},{"key":"10.1016\/j.hrthm.2005.05.020_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0008-6363(01)00521-1","article-title":"Signal transduction systems in atrial fibrillation","volume":"54","author":"Goette","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2005.05.020_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0735-1097(00)00611-2","article-title":"Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation","volume":"35","author":"Goette","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cardiores.2003.08.014","article-title":"Evolution of the atrial fibrillation substrate in experimental congestive heart failure","volume":"60","author":"Cardin","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2005.05.020_bib14","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/hc4601.099402","article-title":"Effects of angiotensin-converting inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure","volume":"104","author":"Li","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0008-6363(02)00243-2","article-title":"Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure","volume":"54","author":"Shi","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2005.05.020_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1536\/jhj.45.93","article-title":"Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation","volume":"45","author":"Hirayama","year":"2004","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.hrthm.2005.05.020_bib17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0735-1097(03)00464-9","article-title":"Effects of angiotensin II type 1 receptor antagonist on electrical remodeling in atrial fibrillation","volume":"41","author":"Kumagai","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib18","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/hc4901.101760","article-title":"C-reactive protein elevation in patients with atrial arrhythmias","volume":"104","author":"Chung","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/01.CIR.104.2.174","article-title":"Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation","volume":"104","author":"Mihm","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.amjcard.2004.07.108","article-title":"Frequency of elevation of C-reactive protein in atrial fibrillation","volume":"94","author":"Anderson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.CIR.0000029743.68247.31","article-title":"Simvastatin lowers C-reactive protein within 14 days","volume":"106","author":"Plenge","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib22","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1161\/01.CIR.102.16.1970","article-title":"Oxidized LDL upregulates angiotensin II type I receptor expression in cultured human coronary artery endothelial cells","volume":"102","author":"Li","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib24","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2004.03.056","article-title":"Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation","volume":"44","author":"L\u2019Allier","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","article-title":"Valsartan reduces the incidence of atrial fibrillation in patients with heart failure","volume":"149","author":"Maggioni","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrthm.2005.05.020_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","article-title":"Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation","volume":"106","author":"Madrid","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib28","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3317\/jraas.2004.027","article-title":"Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers","volume":"5","author":"Madrid","year":"2004","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.hrthm.2005.05.020_bib30","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1540-8159.2004.00645.x","article-title":"The role of angiotensin receptor blockers and\/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases","volume":"27","author":"Madrid","year":"2004","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cardiores.2004.01.018","article-title":"The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model","volume":"62","author":"Kumagai","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2005.05.020_bib32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.amjcard.2003.08.040","article-title":"Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease","volume":"92","author":"Young-Xu","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.amjcard.2003.08.023","article-title":"Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion","volume":"92","author":"Siu","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib34","unstructured":"Merckx KL, Tieleman RG, Folkeringa RJ, Pinto YM, Nieman FH, Cheriex EC, Crijns HJ. Use of statins is associated with reduced incidence of atrial fibrillation in patients with left ventricular hypertrophy and left atrial dilatation. Heart Rhythm 2004;1(1 Suppl 1):Abstract 2004-328: Page S105."},{"key":"10.1016\/j.hrthm.2005.05.020_bib35","unstructured":"Colivicchi F, Ammirati F, Santini M. Effects of statin therapy on the recurrence of persistent atrial fibrillation in patients with essential hypertension: a propensity score-adjusted analysis. Heart Rhythm 2004;1(1 Suppl 1):Abstract 2004-532: Page S168."},{"key":"10.1016\/j.hrthm.2005.05.020_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.amjcard.2003.12.009","article-title":"Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion","volume":"93","author":"Tveit","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2005.05.020_bib38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2005.05.020_bib39","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","article-title":"Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure","volume":"106","author":"Jorde","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2005.05.020_bib40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ehj.2004.04.025","article-title":"Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation","volume":"25","author":"Dernellis","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2005.05.020_bib41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0195-668X(03)00311-7","article-title":"Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrence after an electrical cardioversion","volume":"24","author":"De Simone","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2005.05.020_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9149(02)02450-5","article-title":"Effect of verapamil on secondary cardioversion in patients with early atrial fibrillation recurrence after electrical cardioversion","volume":"90","author":"De Simone","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2005.05.020_bib43","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ehj.2004.04.015","article-title":"Prevention of atrial fibrillation after cardioversion","volume":"25","author":"Fetsch","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2005.05.020_bib44","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ehj.2004.06.014","article-title":"Suppression of paroxysmal atrial tachyarrhythmias","volume":"25","author":"Patten","year":"2004","journal-title":"Eur Heart J"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527105017753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527105017753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:35:57Z","timestamp":1761546957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527105017753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S1547527105017753"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2005.05.020","relation":{},"ISSN":["1547-5271"],"issn-type":[{"type":"print","value":"1547-5271"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2005.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}